Tang Zhao-Xian, Gong Jing-Lin, Wang Ya-Hui, Li Zhen-Hua, He Yun, Liu Yi- Xiu, Zhou Xiao-Hong
Department of ENT, Chongqing Cancer Hospital and Institute and Cancer Center, Chongqing, China.
Medicine (Baltimore). 2018 May;97(21):e10625. doi: 10.1097/MD.0000000000010625.
We aimed to provide a pooled analysis of controlled trials comparing long-term survival after primary laryngectomy and primary organ preservation methods in patients with T3-4 laryngeal cancer.
We performed random-effects meta-analyses on overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), and locoregional control (LRC).
Fifteen studies met the selection criteria including 6288 patients (2696 patients who underwent primary laryngectomy and 3592 patients who underwent primary nonsurgical organ preservation therapy). There was a significant difference between the groups with respect to OS (HR 0.71, 95% CI 0.57-0.89, P = .003). However, a subgroup analysis found OS was not significantly worse for patients with T3 laryngeal cancer who received primary organ preservation compared with patients who underwent primary laryngectomy (HR 0.96, 95% CI 0.45-2.03, P = .91). There was no significant difference for DFS (HR 0.63, 95% CI 0.39-1.04, P = .07) in two groups. Patients with laryngeal cancer who underwent primary laryngectomy had a better DSS (HR 0.47, 95% CI 0.25-0.88, P = .02) and LRC (HR 0.56, 95% CI 0.390.80, P = .001) than patients who underwent primary nonsurgical organ preservation therapy.
Our results support total laryngectomy for patients with T4 laryngeal cancer and show that primary organ preservation for laryngeal cancer has no advantage and also did not decrease the rate of OS in patients with T3 laryngeal cancer when compared with primary total laryngectomy.
我们旨在对比较T3-4期喉癌患者行初次喉切除术和初次器官保留治疗后的长期生存率的对照试验进行汇总分析。
我们对总生存期(OS)、无病生存期(DFS)、疾病特异性生存期(DSS)和局部区域控制(LRC)进行随机效应荟萃分析。
15项研究符合入选标准,包括6288例患者(2696例行初次喉切除术的患者和3592例行初次非手术器官保留治疗的患者)。两组在OS方面存在显著差异(风险比[HR] 0.71,95%置信区间[CI] 0.57 - 0.89,P = 0.003)。然而,亚组分析发现,与行初次喉切除术的患者相比,接受初次器官保留治疗的T3期喉癌患者的OS并无显著更差(HR 0.96,95% CI 0.45 - 2.03,P = 0.91)。两组在DFS方面无显著差异(HR 0.63,95% CI 0.39 - 1.04,P = 0.07)。行初次喉切除术的喉癌患者比接受初次非手术器官保留治疗的患者具有更好的DSS(HR 0.47,95% CI 0.25 - 0.88,P = 0.02)和LRC(HR 0.56,95% CI 0.39 - 0.80,P = 0.001)。
我们的结果支持对T4期喉癌患者行全喉切除术,并表明与初次全喉切除术相比,喉癌的初次器官保留治疗没有优势,也未降低T3期喉癌患者的OS率。